Esperion Therapeutics (ESPR) Net Cash Flow (2012 - 2026)

Esperion Therapeutics has reported Net Cash Flow for 15 years, with the latest figure at -$11.7 million in Q1 2026.

• For the quarter ending Q1 2026, Net Cash Flow rose 61.19% year-over-year to -$11.7 million; the trailing twelve-month figure through Mar 2026 stood at $41.5 million (up 137.08% YoY), and the FY2025 full-year result was $23.1 million, down 63.06% from the prior year.
• Net Cash Flow for Q1 2026 stood at -$11.7 million, down from $75.4 million in the prior quarter.
• The five-year high for Net Cash Flow was $144.4 million in Q1 2024, with the low at -$84.6 million in Q4 2022.
• Historically, Net Cash Flow has averaged -$6.0 million across 5 years, with a median of -$23.6 million in 2023.
• Annual changes were most pronounced in 2022 — Net Cash Flow plunged 2299.2% — and 2025, when it soared 171275.0%.
• Esperion Therapeutics' Net Cash Flow stood at -$84.6 million in 2022, then jumped by 61.49% to -$32.6 million in 2023, then jumped by 100.14% to $44000.0 in 2024, then soared by 171275.0% to $75.4 million in 2025, then sank by 115.51% to -$11.7 million in 2026.
• The last three Net Cash Flow figures came in at -$11.7 million (Q1 2026), $75.4 million (Q4 2025), and $6.4 million (Q3 2025), per Business Quant data.